Efficacy and safety of donanemab in the European eligible population: TRAILBLAZER-ALZ 2 post-hoc analyses.
Saved in:
| Title: | Efficacy and safety of donanemab in the European eligible population: TRAILBLAZER-ALZ 2 post-hoc analyses. |
|---|---|
| Authors: | Jessen F; Department of Psychiatry, Medical Faculty, University of Cologne, Cologne, Germany; German Center for Neurodegenerative Diseases, Bonn, Germany; Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany., Dell'Agnello G; Eli Lilly and Company, Indianapolis, IN, USA. Electronic address: dell_agnello_grazia@lilly.com., Zimmer JA; Eli Lilly and Company, Indianapolis, IN, USA., Sapin C; Eli Lilly and Company, Indianapolis, IN, USA., Dichter S; Eli Lilly and Company, Indianapolis, IN, USA., Doty E; Eli Lilly and Company, Indianapolis, IN, USA., Epelbaum S; Eli Lilly and Company, Indianapolis, IN, USA., Evans CD; Eli Lilly and Company, Indianapolis, IN, USA., Hauck PM; Eli Lilly and Company, Indianapolis, IN, USA., Khanna R; Eli Lilly and Company, Indianapolis, IN, USA., Brooks DA; Eli Lilly and Company, Indianapolis, IN, USA., Sims JR; Eli Lilly and Company, Indianapolis, IN, USA., Agosta F; Unit of Neurology and Neuroimaging of Neurodegenerative Diseases, IRCCS Ospedale San Raffaele, Milano, Italy; 'Vita-Salute San Raffaele' University, Milano, Italy. |
| Corporate Authors: | Alzheimer’s Disease Neuroimaging Initiative (ADNI) |
| Source: | The journal of prevention of Alzheimer's disease [J Prev Alzheimers Dis] 2026 May 27; Vol. 13 (8), pp. 100605. Date of Electronic Publication: 2026 May 27. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer International Publishing Country of Publication: United States NLM ID: 101638820 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2426-0266 (Electronic) Linking ISSN: 22745807 NLM ISO Abbreviation: J Prev Alzheimers Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
